Freeline Therapeutics Holdings plc announced the expansion of its executive leadership team with the appointment of Henning R. Stennicke, PhD, as Chief Scientific Officer (CSO).
Freeline Therapeutics Holdings plc
Equities
FRLN
US35655L2060
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |